Abiogen Pharma   Report issue

For profit Phase 2 Phase 3
Founded: Pisa Italy (1997)

Organization Overview

First Clinical Trial
2006
NCT00415909
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2021

Timeline

NOW
  • Now

Alternative names

Abiogen Pharma

Active Ingredients

Drugs in Phase 3 Trials (1)

vitamin d3 (1 trial)

Drugs in Phase 2 Trials (2)

imatinib (gleevec) (1 trial)

tall-104 cells (1 trial)

Drugs in Other Trials (3)

lactobacillus paracasei (1 trial)

leucine (1 trial)

omega-3 fatty acids (omacor) (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Heart Failure (Phase 3)

Leukemia (Phase 2)

Leukemia, Myelogenous, Chronic, BCR-ABL Positive (Phase 2)

Leukemia, Myeloid (Phase 2)

Vitamin D Deficiency (Phase 3)

Overview

  • Highest Phase: Phase 3
  • # of Trials: 3
  • # of Trial APIs: 6